By John Kennedy ( May 19, 2016, 2:38 PM EDT) -- Actavis and two other drugmakers can't launch a generic version of Depomed Inc.'s painkiller Nucynta until the New Jersey federal judge who oversaw a patent infringement trial between the companies makes a final ruling, an order meant to maintain the status quo after the statutory 30-month stay on generic approval ends Friday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.